Mini-Hyper-CVD Regimen Dosing
The mini-hyper-CVD regimen alternates between two distinct chemotherapy phases, with specific dosing for each drug component based on established protocols for lymphoid malignancies.
Cyclophosphamide-Based Cycles (Cycles 1,3,5,7)
Cyclophosphamide: 300 mg/m² IV every 12 hours for 6 doses (days 1-3)
Vincristine: 1.5 mg/m² IV (maximum 2 mg) on days 1 and 8 1
Doxorubicin: 50 mg/m² IV on day 1 (single dose) 2
Dexamethasone: 6 mg/m² IV or orally daily for 5 days 2
Methotrexate-Based Cycles (Cycles 2,4,6,8)
Methotrexate: High-dose at 3.5 g/m² IV on day 2, administered over several hours 3
- Requires leucovorin rescue: 15 mg IV/PO every 6 hours starting 24 hours after methotrexate infusion, continuing until methotrexate level is <0.05 micromolar 4
- Adequate hydration and urine alkalinization are essential
Cytarabine: 2 g/m² IV every 12 hours for 4 doses (days 2-3) 5
- Note: Original hyper-CVAD used 3 g/m², but the "mini" version reduces this to 2 g/m² to decrease toxicity while maintaining efficacy
Cycle Timing and Duration
- Each cycle is administered every 21 days
- Standard protocol involves 8 total cycles (4 of each type, alternating)
- Recent dose-dense approaches may shorten intervals between cycles 6
Important Dosing Considerations
Age-related modifications: For patients ≥60 years, the regimen is often further attenuated with lower cyclophosphamide doses (150 mg/m² every 12 hours for 6 doses) 1
Intrathecal prophylaxis: Methotrexate 15 mg with cytarabine 40 mg and hydrocortisone 10-15 mg (age-adjusted) administered 4-8 times during treatment 2, 3
Vincristine maximum: Always cap at 2 mg total dose regardless of body surface area to prevent excessive neurotoxicity 7
Common pitfall: The methotrexate dose requires meticulous leucovorin rescue monitoring. Delayed methotrexate elimination (level >0.2 micromolar at 72 hours) necessitates continued leucovorin at 15 mg every 6 hours until levels are safe 4. Renal function must be monitored closely, as impairment dramatically increases methotrexate toxicity.
Growth factor support: Filgrastim (G-CSF) is typically administered starting day 4-5 of each cycle until neutrophil recovery, particularly important given the dose-intensive nature of this regimen 8.